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The majority of deaths from MBC are in patients with hormone receptor (HR) positive,
HER2 negative disease. Endocrine therapy (ET) remains the backbone of treatment
in these cases, improving survival and quality of life. However, treatment can lose
effectiveness due to primary or acquired endocrine resistance. Analysis of mechanisms
of ET resistance has led to the development of a new generation of targeted
therapies for advanced breast cancer. In addition to anti-estrogen therapy with selective
estrogen receptor modulators, aromatase inhibitors, and/or selective estrogen receptor
degraders, combinations with cyclin dependent kinase (CDK) 4/6 inhibitors have led
to substantial progression free survival (PFS) improvements in the first and second
line settings. While the PI3K/AKT/mTOR pathway is known to be an important growth
pathway in HR positive breast cancer, PI3K inhibitors have been disappointing due to
modest effect sizes and significant toxicity. The mTOR inhibitor everolimus significantly
improves progression free survival when added to ET, and recent studies have improved
supportive care allowing less toxicity. While these combination targeted therapies
improve outcomes and often delay initiation of chemotherapy, long term overall survival
data are lacking and data for the ideal strategy for sequencing these agents remains
unclear. Ongoing research evaluating potential biomarkers andmechanisms of resistance
is anticipated to continue to improve outcomes for patients with HR positive metastatic
breast cancer. In this review, we will discuss management and ongoing challenges in the
treatment of advanced HR positive, HER2 negative breast cancer, highlighting single
agent and combination endocrine therapies, targeted therapies including palbociclib,
ribociclib, abemaciclib, and everolimus, and sequencing of therapies in the clinic.
Keywords: breast cancer, endocrine therapy, cyclin dependent kinase inhibitor, endocrine resistance, targeted
therapy
INTRODUCTION
With approximately 250,000 new cases and 40,000 deaths annually, breast cancer is the most
common malignancy and a leading cause of cancer-related death for women in the United States
(1). The majority of breast cancers are hormone receptor positive (HR positive), including estrogen
receptor (ER) and/or progesterone receptor (PR) positive, with endocrine therapy (ET) remaining
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the backbone of therapy (2–4). Approximately 5–10% of breast
cancer patients present with de novometastatic disease, and 30%
of those initially treated with ET for early stage disease will
relapse with metastatic spread (2). In the setting of metastatic
breast cancer (MBC), the goal of treatment is palliative, and ET
plays a crucial role of maintaining disease control, delaying the
need for chemotherapy, and preserving quality of life. Multiple
new agents have been developed to treat patients in the event
of endocrine resistance; however, optimal sequencing of these
therapies has not yet been determined in clinical trials. Herein, we
present a review of the current treatment landscape for optimal
management of HR positive, HER2 negative MBC.
ENDOCRINE THERAPIES
ET includes the selective estrogen receptor modulators (SERMs;
tamoxifen), aromatase inhibitors (AIs; letrozole, anastrozole,
exemestane) and selective estrogen receptor down regulators
(SERDs; fulvestrant). Given the heterogeneity of disease
presentation and patient characteristics, there is no standard
consensus recommendation for the optimal sequencing of
these agents in patients with HR positive breast cancer in the
metastatic setting (5–8). Results from several phase III studies
evaluating single agent and combination endocrine therapy are
detailed in Table 1.
One of the oldest of these therapies is the SERM tamoxifen,
approved by the FDA as adjuvant therapy in 1986 and repeatedly
found to be effective in themetastatic setting. A systematic review
of 86 clinical trials showed an overall response rate (ORR) of
34% for single agent tamoxifen (9). In pre-menopausal patients
with MBC, first-line therapy with ovarian ablation with either
goserelin or buserelin and tamoxifen was associated with a
significant increase in OS when compared to ovarian ablation
alone (HR 0.78, 95% CI 0.63–0.96, p = 0.02), with a significant
improvement in PFS as well (HR 0.70, 95% CI 0.59–0.85)
(10). For post-menopausal patients, in whom estrogen synthesis
occurs in the peripheral tissues through aromatization, treatment
with AIs has largely replaced tamoxifen. There is no clinical
evidence to suggest favoring one AI over another. Although
there are mechanistic differences between the steroidal AI
(exemestane) and non-steroidal AIs (letrozole and anastrozole)
(11), they are not fully cross-resistant (12). AIs have been
associated with improved overall response rate (ORR), time to
progression (TTP) and disease control rate when compared to
tamoxifen (13). A large meta-analysis demonstrated superior
survival for patients receiving AI compared to tamoxifen (HR
0.89, 95% CI 0.80–0.99) (9). Side effect profiles of AIs and
SERMs vary, with AIs increasing rates of bone loss and
musculoskeletal side effects, and tamoxifen carrying an increased
risk of thromboembolic disease and uterine cancer (14).
Treatment with SERDs represents another viable option for
ET. Initial studies of fulvestrant 250mg showed modest anti-
tumor activity, while higher dosing with 500mg has been
found to provide superior disease control and a greater survival
advantage in comparison to AIs (15–18). In the FIRST study
of 205 post-menopausal patients with advanced breast cancer,
fulvestrant 500mg was found to have a superior TTP and a
decreased risk of progression when compared to anastrozole (19).
Subsequent analysis of the FALCON trial comparing fulvestrant
500mg and anastrozole in the first-line metastatic setting found
that fulvestrant was associated with a significant improvement in
PFS (16.6 months vs. 13.8 months, p = 0.048), with similar rates
of adverse events such as arthralgias and hot flashes (20). Of note,
most of the patients in the FALCON study had never received
prior endocrine therapy. While fulvestrant alone remains an
option for endocrine naïve patients in the first line setting, single
agent response rates are low in previously treated patients (21)
and the majority of patients will now receive a CDK4/6 inhibitor,
as discussed later in this review.
COMBINATION ENDOCRINE THERAPY
Combination therapy with anti-endocrine agents is a logical
extension of single agent anti-endocrine therapy, given
the mechanistic differences between the agents. Based on
encouraging preclinical studies, combination treatment with
fulvestrant plus anastrozole was compared to single agent
anastrozole in the FACT and SWOG S0226 trials. Of note, both
trials used a lower fulvestrant dosing schedule (500mg loading,
then 250mgmonthly). In the FACT trial, combination endocrine
therapy did not demonstrate any significant improvement
in TTP or OS (22). In the SWOG S0226 trial, combination
therapy was associated with an improved PFS, [13.5 months
vs. 15.0 months (HR 0.8 95% CI 0.68–0.94; p = 0.007)] and
OS [41.3 months vs. 47.7 months (HR 0.81 95% CI 0.65–1.00;
p = 0.05)] (23). The difference in these results likely has to do
with differing populations in each study. While the SWOG S0226
trial participants were largely treatment naive, approximately
two thirds of participants in the FACT trial had received previous
anti-estrogen therapy.
Given the lack of benefit for combination anti-endocrine
therapy seen in the FACT trial, the South Korean SoFEA trial
was explicitly designed to address the population of MBC
patients with progression on prior non-steroidal AI therapy.
In a randomized three arm trial, combination therapy with
fulvestrant (500mg loading dose and 250mg monthly) plus
anastrozole was compared to fulvestrant plus placebo or single
agent exemestane. No significant differences were identified
between the combination arm and either of the single agent
arms for PFS or OS (24). A subsequent Cochrane Review of
fulvestrant inMBC incorporating 4,514 patients found no benefit
for fulvestrant when used in combination ET in the first or second
line settings (25).
MECHANISMS OF ENDOCRINE
RESISTANCE
Amajor obstacle in the treatment of HR positiveMBC is intrinsic
or acquired resistance to ET. There are multiple oncogenic
drivers and resistance pathways in HR positive breast cancer,
and thorough reviews of these complicated mechanisms can be
found in the literature elsewhere (26–28). Relevant to this review,
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TABLE 1 | Summary of important phase III clinical trial results for endocrine therapy in metastatic HR positive, HER2 negative breast cancer.
Line Study Design n ORR PFS or TTP
HR (95% CI)
OS (months)
HR (if aval.)
1st North American
Trial
Anastrozole 1mg vs.
tamoxifen 20mg
353 21
vs. 17%
11.1 vs. 5.6 mo
1.44 (1.16)
40.4 vs. 38.5
1.02 (0.81-NR)
ILBCG Letrozole 2.5mg vs.
tamoxifen 20mg
907 32
vs. 21%
9.4 vs. 6.0 mo
0.70 (0.60–0.82)
34 vs. 30
EORTS Exemestane 25mg
vs. tamoxifen 20mg
371 46
vs. 31%
9.9 vs. 5.8 mo 37.2 vs. 43.3
FIRST (phase II) Fulvestrant 500mg
vs. anastrozole 1mg
205 31.4
vs. 31.1 23.4 vs. 13.1 mo
0.66 (0.47–0.92)
54.1 vs. 48.4
0.70 (0.50–0.98)
FACT Fulvestrant 250mg + anastrozole
1mg
vs. anastrozole 1mg
514 31.8
vs. 33.6%
10.8 vs. 10.2 mo
0.99 (0.81–1.20)
37.8 vs. 38.2
1.0 (0.76–1.32)
FALCON Fulvestrant 500mg
vs. anastrozole 1mg
562 46
vs. 45%
16.6 vs. 13.8 mo
0.80 (0.64-1.00)
Pending
S0226 Fulvestrant 250mg + anastrozole
1mg
vs. anastrozole 1mg
707 27
vs. 22%
13.5 vs. 15.0 mo
0.80 (0.68-0.94)
41.3 vs. 47.7
0.81 (0.65–1.00)
2nd SoFEA Fulvestrant 250mg + anastrozole
or placebo vs. exemestane (PD on
NSAI)
723 7
vs. 7 vs. 4%
4.4 vs. 4.8 vs. 3.4 mo Not reported
EFECT Fulvestrant 250mg
vs. exemestane 25 (PD on NSAI)
693 7.4
vs. 6.7%
3.7 vs. 3.7 mo
0.93 (0.82–1.13)
Not reported
CONFIRM Fulvestrant 250mg
vs. fulvestrant 500
(PD on ET)
736 10.2
vs. 9.1%
6.5 vs. 5.5 mo
0.80 (0.68–0.94)
26.4 vs. 22.3
0.81 (0.69–0.96)
ORR, overall response rate; PFS, progression free survival; TTP, time of progression; HR, hazard ratio; OS, overall survival; NSAI, nonsteroidal aromatase inhibitor; ET, endocrine therapy.
several resistance mechanisms have led to the development
of therapeutic strategies, including dysregulation of cell cycle
progression, activation of the PI3K/AKT/mammalian target of
rapamycin (mTOR) pathway, and ESR1mutations.
Upregulation of cell cycle regulating molecules, especially
those involved in progression of cells from the G1 to S phases,
can contribute to endocrine resistance (26). Preclinical work
identified CDK4 as critical for growth of ER positive breast cancer
cells resistant to estrogen deprivation (29). Further, in vitro
models of fulvestrant resistant breast cancers revealed increased
expression of CDK6 when compared to fulvestrant sensitive
cells. CDK4/6 is activated when bound to cyclin D1 in the
mid-to-late G1 phase of the cell cycle. CDK4/6 phosphorylates
Rb to inactivate its repressive hold on E2F-mediated cell cycle
progression (30, 31). CDK4/6 activity is particularly relevant in
ER positive breast cancers, given that the cyclin D1 gene CCND1
is regulated by ERα (32). Laboratory and clinical studies confirm
that CDK4/6 inhibitors potently decrease growth of ER positive
breast cancers (33–35). Biomarker analysis of 91 patients with
resistance to fulvestrant demonstrated that elevated CDK6 levels
associated with a shorter PFS (36).
Molecularly, estrogen activity can induce activation of insulin-
like growth factor and the PI3K/AKT and MAPK (mitogen
activated protein kinase) pathways, which can downregulate ER
and PR cell surface expression (37–41). Increased PI3K/AKT
signaling can also result in hormone receptor deactivation,
and promote ligand independent growth of malignancies
in the absence of endocrine signaling. PI3K/AKT signaling
has also been demonstrated to directly phosphorylate the
estrogen receptor, resulting in estrogen independent activation
of hormone receptors and providing a secondary mechanism of
ET resistance (42). PTEN (phosphatase and tensin homolog) is a
negative regulator of the PI3K pathway, and PTEN expression is
downregulated in the setting of endocrine resistance (43).
Multiple genomic alterations have been identified in MBCs
with both intrinsic and acquired resistance, including in ESR1,
resulting in constitutive activation of ER. In correlative analysis of
several trials, frequency of ESR1 mutations in circulating tumor
DNA (ctDNA) is between 25 and 39% (44–46). ESR1 mutations
have been linked to poorer outcomes in patients treated with AI
based therapies. In a secondary analysis of the BOLERO-2 trial of
exemestane with or without the mTOR inhibitor everolimus, the
presence of an ESR1 mutation was associated with reduced OS
(47). Data have suggested that SERDs, such as fulvestrant, may
overcome ESRmutations. In the SoFEA study, patients the ESR1
mutated tumors had significantly worse outcomes when treated
with exemestane, but not when treated with fulvestrant (HR 0.52,
95% CI 0.30–0.92, p= 0.02) (44).
Given the effectiveness of ET in the HR positive population,
therapies designed to overcome de novo or acquired resistance
targeting the aforementioned signaling and cell cycle regulating
molecules may be particularly effective at extending OS and
PFS in this population. In the next section, we review the
small molecule inhibitors that have been approved or are being
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investigated in combination with antiestrogens for the treatment
of post-menopausal women with advanced HR positive, HER2
negative breast cancer in the first or later line settings, targeting
both intrinsic and acquired resistance.
CDK4/6 Inhibitors
Palbociclib
Palbociclib was originally reported in 2009 as PD032991 and
noted to selectively inhibit cyclin-dependent kinases 4 and
6, which resulted in selective inhibition of the proliferation
of luminal ER positive breast cancer cell lines, while non-
luminal basal cell lines were largely resistant to treatment.
Molecular analysis of these cell lines revealed that phosphorylated
retinoblastoma (Rb) and cyclin D1 were elevated while p16 was
decreased in sensitive luminal cell lines. This Rb phosphorylation
was inhibited by treatment with palbociclib resulting in G0/G1
cell cycle arrest (48). It is important to note that while the
anti-proliferative effects of palbociclib were synergistic with anti-
estrogen and anti-HER2 therapy in sensitive cell lines (48),
in triple negative breast cancer and RB1-proficient cell lines,
palbociclib was actually antagonistic to anthracycline mediated
cytotoxicity (49). The dose limiting toxicity of palbociclib
is neutropenia resulting from cell cycle arrest of marrow
hematopoietic stem cells and precursors. This is reversible upon
discontinuation of the drug, in contrast to chemotherapeutic
agents such as paclitaxel or doxorubicin (50).
PALOMA-1/TRIO-18, a phase II study, assessed the safety and
efficacy of palbociclib in conjunction with letrozole as first line
treatment of HR positive, HER2 negative advanced breast cancer.
The study examined two cohorts, enrolling the first based on
receptor status, while the second was enrolled afterwards with
additional requirements for amplification of cyclin D1, loss of
p16, or both. Both cohorts were randomized (1:1) to receive
letrozole 2.5mg daily with or without oral palbociclib 125mg
daily for 21 days out of a 28-day cycle. The primary endpoint
of investigator determined PFS was found to be 10.2 months for
letrozole alone, compared to 20.2 months for palbociclib plus
letrozole (HR 0.49, 95% CI 0.32–0.75, p = 0.0004). In cohort 1,
PFS was 26.1 months for the palbociclib plus letrozole group,
vs. 5.7 months for letrozole alone (HR 0.30, 95% CI 0.16–0.57,
p < 0.0001). In the second cohort with potential biomarkers,
PFS was 18.1 months for the palbociclib plus letrozole group,
vs. 11.1 months with letrozole alone (HR 0.51, 95% CI 0.30–
0.85, p = 0.0046). Accrual to cohort 2 was stopped early due
to unplanned interim analysis of cohort 1 and amendment
of planned combined cohort analysis. The different outcomes
between cohorts 1 and 2 suggested a different behavior of the
CCND1 amplified or p16 deficient tumors, and support ER
positivity as the most important biomarker for response to AI
plus CDK4/6 inhibition, with additional molecular markers of
response remaining elusive, as discussed below. In the toxicity
analysis, grade 3–4 side effects were more common in the
palbociclib group, with neutropenia (54 vs. 1%) leukopenia (19
vs. 1%) and fatigue (4 vs. 1%) being themost common (33). Based
on the results of the PALOMA-1/TRIO 18 study, palbociclib
received accelerated approval in combination with letrozole for
first line therapy for post-menopausal women with advanced HR
positive, HER2 negative breast cancer and subsequent therapy
after progression on prior endocrine therapy (51). The follow up
phase III study, PALOMA-2, confirmed these results, leading to
regular approval of palbociclib (52).
In PALOMA-3, a double-blind phase III study to assess
the efficacy and safety of palbociclib plus fulvestrant in ET
resistant (define as progression on ET or relapse within 12
months of adjuvant ET) HR positive metastatic breast cancer,
the combination of palbociclib plus fulvestrant was associated
with significant improvement in PFS compared to fulvestrant
and placebo. Median PFS was 9.5 months in the fulvestrant plus
palbociclib group, compared to 4.6 months in the fulvestrant plus
placebo group (HR 0.46, 95% CI 0.36–0.59, p < 0.0001) (53).
Analysis of patient reported outcomes revealed that treatment
with palbociclib plus fulvestrant resulted in higher global quality
of life scores and significant reduction in pain when compared to
fulvestrant alone (54).
Ribociclib
Ribociclib, originally designated LEE011, is an oral small
molecule inhibitor of CDK4/6 similar to palbociclib (55). In
preclinical models, ribociclib was found to be highly selective for
CDK4/6 and function primarily with G1 arrest and regression
in some animal models (56). Ribociclib was approved based up
on the MONALEESA-2 study, a phase III randomized, double-
blind trial of 668 patients evaluating ribociclib plus letrozole
for first line treatment of women with HR positive, HER2
negative MBC. The trial was stopped early after a preplanned
interim analysis revealed a significant advantage for the ribociclib
containing arm. With a median follow up of 15.3 months, the
PFS was significantly longer in the ribociclib containing arm (HR
0.56; 95% CI, 0.43–0.72; p < 0.001). Updated analyses show a
median PFS of 25.3 months with ribociclib vs. 16.0 months for
placebo (57). Common grade 3/4 adverse events in the ribociclib
group were neutropenia (59.3 vs. 0.9%) and leukopenia (21.0 vs.
0.6%) (35). MONALEESA-3 is a phase III study of fulvestrant
in combination with ribociclib or placebo for both first and
second line treatment of HR positive, HER2 negative MBC,
with results reported at the 2018 American Society of Clinical
Oncology annual meeting. Consistent with other trials, PFS was
significantly improved in both the first line (HR 0.577, 95% CI
0.42–0.80) and second line/early relapse settings (HR 0.565, 95%
CI 0.43–0.74) (58).
MONALEESA-7 specifically addressed the pre-menopausal
group. Presented at the 2017 San Antonio Breast Cancer
Symposium (SABCS), this phase III trial compared ribociclib
vs. placebo in pre-menopausal woman receiving an AI or
tamoxifen with ovarian suppression. Median PFS again favored
the ribociclib arm (23.8 vs. 13.0 months, HR 0.55, 95% CI
0.44–0.69, p < 0.0001) (59).
Abemaciclib
Abemaciclib is the third agent in the class of CDK4/6 inhibitors
that is currently FDA approved.
MONARCH-2, a global, double-blind phase III trial
investigating abemaciclib in combination with fulvestrant
compared to fulvestrant alone in HR positive, HER2 negative
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MBC with progression on prior ET, demonstrated an improved
PFS with the combination therapy (16.4 vs. 9.3 months,
HR 0.553, 95% CI 0.449–0.681, p < 0.001). Treatment with
abemaciclib was associated with increased rates of diarrhea (86.4
vs. 24.7%), neutropenia (46.0 vs. 4.0%), nausea (45.1 vs. 22.9%),
and fatigue (39.9 vs. 26.9%), as well as an increased rate of
thromboembolic events (2.0 vs. 0.4%) (60). Results of the phase
III study of abemaciclib in combination with a non-steroidal
AI (MONARCH-3) were recently reported (61). This study
allowed the treating physician to determine the non-steroidal AI
utilized (79.1% letrozole, 20.9% anastrozole). Interim analysis
was conducted following 194 PFS events with a median follow
up of 17.8 months. Abemaciclib was associated with improved
PFS (14.7 months vs. not reached, HR 0.543, 95% CI 0.41–0.72;
p < 0.001).
MONARCH-1, a phase II single arm study, evaluated the
safety and efficacy of abemaciclib monotherapy in patients
with HR positive, HER2 negative metastatic breast cancer of
any menopausal status, whose disease had progressed on prior
endocrine and chemotherapy. At the time of interim analysis 132
patients had been treated with abemaciclib 200mg twice daily as
monotherapy, with a median of three lines of prior therapy and
over 90% having visceral disease. At 12 months, the ORR was
19.7%, median PFS of 6.0 months, andmedian OS of 17.7 months
(62).
Comparative Efficacy, Sequencing, and Biomarkers
Palbociclib, ribociclib, and abemaciclib have never been directly
compared and have resulted in similar effect sizes (see Table 2).
Differences in median PFS are attributable to differing patient
populations between studies, with similar hazard ratios in studies
across the three approved CDK4/6 inhibitors. After the 2018
ASCO annual meeting, we have results for all of these agents
both in the first line setting with AIs and the second line setting
in combination with fulvestrant. In addition, MONALESSA-7
and analyses from PALOMA-3 and MONARCH-2 have shown
similar efficacy for CDK4/6 inhibitors in combination with ET
and ovarian suppression for pre-menopausal women, confirming
what many oncologists were already doing in practice (59, 63).
While the three agents likely have similar efficacy, the toxicity
profiles, dosing schedules, and monitoring required differ (64).
Palbociclib and ribociclib, given on a 3 weeks on and 1 week
off schedule, both have dose limiting toxicity of neutropenia,
while the dose limiting toxicity for daily abemaciclib is diarrhea,
perhaps due to its greater affinity for CDK4 over CDK6.
Complete blood count (CBC) monitoring is required for all
agents. Ribociclib uniquely requires monitoring of liver function
tests, electrolytes, and the QT interval. Abemaciclib requires
liver function test monitoring as well, and may increase risk
of thromboembolic disease. There is no specific benefit of
one toxicity profile over another, and patient comorbidities,
preferences, and physician familiarity dictate choice between
these agents. Packaging provided by drug companies also differs
between the agents, with the blister packaging of ribociclib
potentially allowing for dose reduction in a more timely manner
without the need for a new prescription. Importantly, the
financial toxicity of each of these agents can be significant.
While the data for the use of CDK4/6 inhibitors in the first
or second line has been impressive, questions remain. Overall
survival data from the larger, randomized trials remains to be
seen and will likely be difficult to interpret given the long natural
history of HR positive MBC. In addition, data clarifying when
it is best to sequence a CDK4/6 inhibitor in the course of a
patient’s therapy options are lacking. Regardless, PFS, quality of
life, and delay of chemotherapy are important clinical benefits
in the absence of survival data, and it is likely that receiving
a CDK4/6 inhibitor at some point is better than never having
received one. The decision of use in the first or second line should
be based on disease characteristics and patient preference. While
the majority of patients will likely receive a CDK4/6 inhibitor
in the first line setting, select patients with a long disease-
free interval after adjuvant ET, or small volume or bone-only
disease, are likely to have a long PFS interval with ET therapy
alone and may opt to delay CDK4/6 inhibitor initiation to a
later line.
Despite the promising results, approximately 20% of patients
will not respond to CDK4/6 inhibitors and the majority will
develop resistance. Thus far, there has been no subgroup or
clinical population that does not derive benefit from CDK4/6
inhibitors, including age, menopausal status, visceral vs. bone
metastases, race, or treatment free interval. In addition, an
FDA pooled analysis looking at rarer clinical subtypes, including
lobular disease, PR negative, or de novo MBC, found continued
benefit to all subtypes (65). It is important to note that the
CDK4/6 inhibitors have high and potentially rapid response rates
in patients with even advanced visceral disease, and can therefore
be used instead of chemotherapy in the absence of true “visceral
crisis.”
In addition to clinical subtypes, there has been a consistent
benefit to CDK4/6 inhibitors across molecular biomarkers
thought to be involved in resistance, including pRb, p16,
Ki67, ESR1 expression, CDKN2A expression, CCND1
expression, PI3KCA mutations, and ESR1 mutations, among
others. An abstract presented at the 2018 ASCO annual
meeting looking at mRNA expression in MONALESSA-
2 found a trend toward longer PFS with higher ESR1
expression, and a trend toward more benefit from ribociclib
with high ESR1 expression, compared to low (HR 0.39
vs. HR 0.74) (66). Mechanisms of resistance to CDK4/6
inhibitors are reviewed elsewhere and thought to include
cyclin E amplification, Rb loss, CDK2 overexpression,
FGFR1 amplification or mutation, and upregulation of
the PI3k/AKT pathway (67, 68). These investigations have
led to the development of clinical trials assessing drug
combinations, including CDK4/6 inhibition with PI3K or mTOR
inhibitors.
PI3K/AKT/mTOR Inhibitors
mTOR Inhibitors
mTOR is a PI3K kinase with roles in the regulation of PI3K
signaling and regulation of protein synthesis and cell growth
(69). In breast cancer, activated mTOR signaling is associated
with poor patient survival (70) and worse prognosis (71). mTOR
can be activated by activating mutations in the PIK3CA gene
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TABLE 2 | Summary of phase III clinical trial results for CDK4/6 inhibitors in metastatic HR positive, HER2 negative breast cancer.
Line Study Investigational arm n ORR Median PFS
HR (95% CI)
OS
1st PALOMA-2 Palbociclib/letrozole 666 55
vs. 39.0%
24.8 vs. 14.5 mo
0.58 (0.46–0.72)
Pending
MONALEESA-
2
Ribociclib/letrozole 668 54.5
vs. 38.8%
25.3 vs. 16.0 mo
0.57 (0.46–0.70)
Pending
MONARCH-3 Abemaciclib/NSAI 493 59.0
vs. 44.0%
28.1 vs. 14.7 mo
0.54 (0.41–0.72)
Pending
MONALEESA-
7
RIbociclib/AI or
tam+OFS
672 51.0
vs. 36.0%
23.8 vs. 13.0 mo
0.55 (0.44–0.69)
Pending
2nd PALOMA-3 Palbociclib/
Fulvestrant
521 24.6
vs. 10.9%
9.5 vs. 4.6 mo
0.46 (0.36–0.59)
Not yet
reported
MONARCH-2 Abemaciclib/
fulvestrant
669 48.1
vs. 21.3%
16.4 vs. 9.3 mo
0.55 (0.45–0.68)
Pending
MONALEESA-
3
RIbociclib/
fulvestrant
726 41.0
vs. 29.0%
20.5 vs. 12.8 mo
0.59 (0.48–0.73)
Pending
Later MONARCH-
1* Phase
II
Abemaciclib (single
arm)
132 19.7%
6.0 mo
17.7 mo
ORR, overall response rate; PFS, progression free survival; HR, hazard ratio; OS, overall survival; NSAI, nonsteroidal aromatase inhibitor.
(72), alteration or mutation of AKT, or loss of PTEN signaling
(73). mTOR activation has been associated with resistance to
SERMs and AIs (74, 75) and inhibition of the mTOR pathway is
associated with resensitization of breast cancer cells to hormonal
therapy (76). In breast cancer cells resistant to AI, treatment
with the mTOR inhibitor everolimus has been associated with
dramatically reduced ER expression and increased autophagy in
MCF-7 breast cancer cell lines (77, 78). Results from phase III
trials assessing agents in this pathway are summarized in Table 3.
Based on preclinical and neoadjuvant data, the combination of
everolimus plus exemestane was assessed for efficacy and safety in
patients withHR positive, HER2 negative breast cancer refractory
to non-steroidal AIs in the international double-blind phase III
BOLERO-2 study. The primary end point of PFS was met by
the study, with the advantage for the combination arm (6.9 vs.
2.8 months, HR 0.43, 95% CI 0.35–0.54, p < 0.001). Twenty-
three percent of patients treated with everolimus reported
serious adverse events, and 19% of patients (4% treated with
placebo) discontinued therapy due to adverse events. The most
common grade 3/4 toxicities were stomatitis (8%), anemia (6%),
dyspnea (4%), and pneumonitis (3%) (79). Further analysis in
the BALLET study of everolimus and exemestane in patients
previously treated with or without chemotherapy, found a high
rate of adverse events, the most common being stomatitis
(51.3%) and confirmed the safety profile was not affected by
prior chemotherapy (80). In addition, despite the increased
toxicity, there was no evidence of statistically significant
improvement in OS (hazard ratio 0.89; 95% CI 0.73–1.10;
P = 0.14) (81).
As stomatitis has been a consistent problem in completing
everolimus therapy, the phase II SWISH study investigated
the use of prophylactic steroid mouthwash. Of the 85 women
evaluable for efficacy, only 2% had grade 2 or worse stomatitis,
vs. 33% historically in BOLERO-2 (82). A similar phase III trial
(Oral Care-BC) is investigating the impact of professional dental
cleanings by oral surgeons on the incidence of oral mucositis with
everolimus therapy. The study is still accruing with estimated
primary completion date of March 2019 (NCT02376985) (83).
Vistusertib, an oral dual inhibitor of mTORC1 and mTORC2,
was superior to everolimus (an mTORC1 inhibitor) in preclinical
models and therefore was investigated in the phase II randomized
study MANTA, evaluating fulvestrant alone versus fulvestrant
with daily vistusertib, fulvestrant with intermittent vistusertib,
and fulvestrant with everolimus. No significant difference was
seen between the arms, with the exception of improved PFS in
the fulvestrant with everolimus arm compared to fulvestrant with
vistusertib (HR 0.64, 95% CI 0.45–0.91, p= 0.01), and fulvestrant
with everolimus compared to fulvestrant alone (HR 0.64, 95% CI
0.43–0.94, p= 0.02) (84).
PI3K Inhibitors
PI3K/AKT signaling plays an important role in the growth and
proliferation of tumor cells by acting upstream of the mTOR
signaling pathway. This signaling pathway is tightly regulated
by the tumor repressor genes PTEN and INPP4B, which are
frequently downregulated in breast malignancies, resulting in
amplification of the PI3K/AKT/mTOR signal (85). PIK3CA
mutations are also frequently mutated in HR positive breast
cancer and are frequently associated with the luminal B subtype
of breast cancer (86). Although PIK3CAmutations are frequently
detected in breast cancers [32% in TCGA (87–89)], they have
not been associated with clinical outcome (87) or influenced
OS (90). However, in multivariate analysis, PIK3CA mutation in
conjunction with node positive disease has been associated with
unfavorable OS (87).
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TABLE 3 | Summary of phase III clinical trial results for PI3K and mTOR inhibitors in metastatic HR positive, HER2 negative breast cancer.
Line Study Investigational
arm
n ORR Median PFS
HR (95% CI)
OS
2nd BOLERO-2 Everolimus/
exemestane
724 9.5 vs.
0.4%
6.9 vs. 2.8 mo
0.43 (0.35–0.54)
31.0 vs. 26.6 mo
0.89 (0.73–1.1)
BELLE-2 Buparlisib/
fulvestrant
1,147 11.8
vs. 7.7%
6.9 vs. 5.0 mo
0.78 (0.67–0.89)
Pending
BELLE-3 Buparlisib/
fulvestrant
432 22 vs.
3%
3.9 vs. 1.8 mo
0.67 (0.53–0.84)
Pending
SANDPIPER Talelisib/
fulvestrant
516 Pi3K
mutants
28 vs.
11.9%
7.4 vs. 5.4 mo
0.70 (0.56–0.89)
Pending
ORR, overall response rate; PFS, progression free survival; HR, hazard ratio; OS, overall survival.
There are currently no PI3K inhibitors approved for HR
positive breast cancer, although several are in registration trials.
The most heavily studied has been buparlisib (BKM120), an
oral pan-PI3K inhibitor under examination in the BELLE-
2 (NCT01610284) and BELLE-3 (NCT01633060) phase III
clinical trials in combination with fulvestrant in HR positive,
HER2 negative, locally advanced, or MBC refractory to AI or
AI+mTOR inhibitor, respectively. In BELLE-2, initial PFS data
shows a significant advantage for the buparlisib arm (6.9 vs. 5.0
months, HR 0.78, 95% CI 0.67–0.89, p < 0.001). In BELLE-3,
similar results were seen favoring the buparlisib arm, but PFS
was short (3.9 vs. 1.8 months, HR 0.67, 95% CI 0.53–0.84),
p < 0.001). On retrospective analysis of ctDNA, the benefit
was restricted to the PIK3CA mutated group, while this was
not seen in BELLE-3. In addition, significant side effects were
seen, including elevated liver function tests, hyperglycemia,
anxiety, and depression, resulting in dose delay and
interruption (91, 92).
Taselisib (GDC-0032), a selective PI3K inhibitor with greater
in vitro activity against mutant isoforms, has been studied in the
phase III SANDPIPER trial, with initial results recently reported.
Patients with PIK3CA mutated tumors with progression on
prior AI were randomized 2:1 to taselisib with fulvestrant or
placebo with fulvestrant. An exploratory arm enrolled patients
with wild type tumors. In the mutated arms, PFS was improved
with the addition of taselisib (7.4 vs. 5.4 months, HR 0.70,
p = 0.0037). In the exploratory wild type group, there was no
difference between the arms, but sample size was small. Fifty
percent of patients in the investigational arm developed grade
3 or 4 toxicity, and the majority of patients discontinued
treatment due to adverse events, diarrhea being most
common (93).
While clinical trials have shown proof of concept for PI3K
inhibition in endocrine resistance, themodest efficacy, significant
toxicity, and unclear use within the CDK4/6 inhibitor spectrum
will likely limit future development of these compounds.
In addition to PI3K inhibitors, several other classes of
agents are under investigation to combat endocrine resistance
but have yet to provide phase III clinical trial results. Several
FGFR inhibitors are under investigation both in combination
with endocrine therapy and with other targeted therapies (94).
The oral histone deacetylase (HDAC) inhibitor entinostat in
combination with exemestane improved DFS and OS over
exemestane alone in a phase II trial (95) and the randomized
phase III study is ongoing (NCT02115282).
CONCLUSIONS
HR positive breast cancer is responsible for the majority
of breast cancer related deaths. Although outcomes for HR
positive breast cancer are excellent in early disease, in the
advanced setting, outcomes remain poor with more women
dying from HR positive breast cancer than other subtypes
combined. In an era of personalized medicine with four
small molecule inhibitors already FDA-approved (everolimus,
pabociclib, riboclicib, abemaciclib), in addition to others under
clinical investigation, the question of how to tailor therapy for
patients in this setting is very relevant. Currently there is a lack of
definitive biomarkers to identify specific patient populations that
will benefit more from one targeted therapy over another.
Without clear biomarkers, selection of ET in the first line
metastatic setting depends on clinician/patient preferences,
disease burden, and disease biology. While endocrine therapy
alone, including aromatase inhibitors, tamoxifen, or fulvestrant,
may be appropriate for select patients, the consistent benefits
of CDK4/6 inhibitors across multiple subgroups, including
those with longer disease free intervals, support their use
in the first line for most patients while we await overall
survival data. Options for the ET backbone include AIs or
fulvestrant for post-menopausal patients, and tamoxifen, AI,
or fulvestrant with ovarian suppression for pre-menopausal
patients. For most patients, AI (with or without ovarian
suppression) and a CDK4/6 inhibitor will likely be most
appropriate, with fulvestrant plus CDK4/6 inhibitor used in those
who relapsed while on or within 12 months of adjuvant AI
therapy, or those with a known ESR1mutation. Again, individual
patient comorbidities, preferences for drug administration,
and access should play a role in selection of first line
therapy.
In the event of progression, second line treatment should
include a CDK4/6 inhibitor if not used in the first line setting.
While we await data on the utility of continued CDK4/6
inhibition or switching agents after progression, options for
patients after progression include fulvestrant or an AI alone
if not previously used, or exemestane with everolimus. We
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are in favor of enrollment in clinical trials for patients with
CDK4/6 inhibitor resistance, including, but not limited to, the
MAINTAIN trial evaluating fulvestrant with or without ribociclib
after progression on palbociclib or ribociclib (NCT02632045);
PACE evaluating fulvestrant, fulvestrant with palbociclib, or
fulvestrant with palbociclib plus the anti-PD-1 avelumab
in patients progressing on palbociclib (NCT03147287), or
TRINITI, evaluating ribociclib with everolimus and exemestane
after prior CDK4/6 inhibitor treatment (NCT02732119). For
patients progressing rapidly through ET, standard cytotoxic
chemotherapy can be tried.
Continued work to evaluate biomarkers of resistance may
lead us in the future to a precision medicine approach to
therapy after CDK4/6 inhibitor resistance develops. Recent data
evaluating ctDNA before and after CD4/6 inhibitor treatment
in PALOMA-3 showed the development of Rb, PIK3CA, and
ESR1 mutations (96). This study indicated feasibility of detecting
genomic changes in the blood, which might guide us to alter
therapy in a targeted way. Correlative studies from the ongoing
trials mentioned above will likely begin to help us answer these
questions.
Single agent endocrine therapy and combinations with
targeted therapy offer a range of options for patients with
metastatic HR positive breast cancer. Currently, the optimal
sequencing of these therapies is unclear, and should be based
on patient characteristics, clinical judgement, and disease
biology. While sequential lines of ET combinations can improve
outcomes for patients, many acquire endocrine resistance.
Ongoing research to identify biomarkers and optimal sequencing
for individual patients is awaited, with hopes to continue to
improve outcomes and quality of life for patients with HR
positive metastatic breast cancer.
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